-$0.34 Earnings Per Share Expected for Idera Pharmaceuticals Inc (NASDAQ:IDRA) This Quarter

Wall Street analysts predict that Idera Pharmaceuticals Inc (NASDAQ:IDRA) will announce earnings of ($0.34) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Idera Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.41) and the highest is ($0.21). Idera Pharmaceuticals posted earnings of ($0.45) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 24.4%. The firm is expected to announce its next earnings results on Wednesday, March 4th.

According to Zacks, analysts expect that Idera Pharmaceuticals will report full-year earnings of ($1.51) per share for the current year, with EPS estimates ranging from ($1.60) to ($1.28). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.25) per share, with EPS estimates ranging from ($1.79) to ($0.70). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Idera Pharmaceuticals.

Idera Pharmaceuticals (NASDAQ:IDRA) last posted its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.07.

Several equities research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating on shares of Idera Pharmaceuticals in a research note on Thursday. ValuEngine upgraded Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research lowered Idera Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 15th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $7.00 price objective on shares of Idera Pharmaceuticals in a research note on Thursday, September 5th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Idera Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $7.63.

Shares of NASDAQ IDRA traded down $0.09 during trading hours on Tuesday, hitting $2.39. 74,000 shares of the company’s stock were exchanged, compared to its average volume of 275,491. Idera Pharmaceuticals has a 1-year low of $2.08 and a 1-year high of $8.95. The stock has a market capitalization of $76.15 million, a price-to-earnings ratio of -1.05 and a beta of 2.38. The company’s 50-day moving average price is $2.66 and its 200-day moving average price is $2.66.

In related news, major shareholder Invest Corp Pillar sold 100,000 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $2.50, for a total transaction of $250,000.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 3.46% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IDRA. GSA Capital Partners LLP boosted its position in Idera Pharmaceuticals by 50.2% in the 2nd quarter. GSA Capital Partners LLP now owns 98,309 shares of the biotechnology company’s stock valued at $262,000 after buying an additional 32,861 shares during the last quarter. Acadian Asset Management LLC boosted its position in Idera Pharmaceuticals by 273.5% in the 2nd quarter. Acadian Asset Management LLC now owns 165,044 shares of the biotechnology company’s stock valued at $440,000 after buying an additional 120,861 shares during the last quarter. Paloma Partners Management Co bought a new position in Idera Pharmaceuticals in the 2nd quarter valued at $228,000. Parametric Portfolio Associates LLC bought a new position in Idera Pharmaceuticals in the 2nd quarter valued at $44,000. Finally, Natixis boosted its position in Idera Pharmaceuticals by 61.7% in the 2nd quarter. Natixis now owns 743,618 shares of the biotechnology company’s stock valued at $1,985,000 after buying an additional 283,802 shares during the last quarter. Institutional investors and hedge funds own 36.12% of the company’s stock.

About Idera Pharmaceuticals

Idera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer.

See Also: Special Dividends

Get a free copy of the Zacks research report on Idera Pharmaceuticals (IDRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Idera Pharmaceuticals (NASDAQ:IDRA)

Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.